Ozempic & GLP-1 Lawsuit Leads for Law Firms - Since 2009

Ozempic Lawsuit Leads That Survive the Court's New Standard

The GLP-1 litigation moved from volume to evidence. The federal court now requires objective diagnostic proof to keep a gastroparesis claim alive - and an unverified name is a file the MDL will throw out. We deliver exclusive, pre-verified Ozempic claimants - gastroparesis and NAION vision loss - screened to the exact standard MDL 3094 and 3163 now demand. Qualified claimants matched to your criteria, or you don't pay.

Get Your Ozempic Leads Quote Call (800) 889-1679

60K+Leads Delivered

3–5Days to First Lead

15+Years Experience

The Litigation Moved

The Court Raised the Bar.
Most Leads Didn't.

In 2024, an Ozempic lead was a name and a side effect. In 2026, that same lead is a file the MDL throws out. Here's what changed - and why it decides whether the inventory you buy is worth anything.

2024 · The Old Way

A Name and a Symptom

Early GLP-1 intake was volume-first. A claimant who simply said they'd had stomach trouble after Ozempic was treated as a case.

Self-reported symptoms accepted as qualifying
No diagnostic proof captured at intake
"Spray and pray" volume now worthless

2026 · The Court's Standard

Objective Proof, or No Case

The judge overseeing the GLP-1 MDLs now requires gastroparesis plaintiffs to back the diagnosis with objective testing. NAION claims need formal ophthalmologic confirmation.

Diagnosis confirmed by objective testing
Verified files hold value through Daubert
Screening to the standard is the price of entry

We don't sell the raw name the court will reject. We sell the verified file the court now requires - screened to the exact standard that decides whether your case survives in MDL 3094 and 3163.

Why This Is Your Moat

Every Lead, Screened to the Diagnosis That Holds Up

Here's the part most firms learn the expensive way. After the court's ruling, an unverified gastroparesis claim was immediately discounted - and with defense Daubert challenges testing the plaintiffs' experts, any case that can't show the science faces further pressure.

So we capture diagnostic posture before a lead ever reaches you. When you buy from us, you're not just buying a claimant - you're buying one already on the right side of the line the court drew.

A confirmed diagnosis is no longer a "nice to have." It is the difference between a file you can litigate and an intake hour you'll never get back.

Gastric emptying study (scintigraphy) and diagnostic imaging used to confirm GLP-1 gastroparesis claims to the MDL standard

Accepted Diagnostic Proof We Screen For

Gastric Emptying Study (Scintigraphy)The court's "gold standard" - a tagged meal tracked as it leaves the stomach. We confirm whether the claimant has it.

Wireless Motility Capsule (WMC)An accepted alternative measuring transit through the GI tract - captured and flagged in the file.

Gastric Emptying Breath TestThe third validated route to a defensible gastroparesis diagnosis under the MDL's order.

NAION Ophthalmologic ConfirmationFor vision-loss claims: formal diagnosis by an ophthalmologist or neuro-ophthalmologist, with mimics ruled out.

We capture diagnostic status at intake and flag it on every delivered file, so your team knows exactly what it's working with.

Know the Claimant You Want

Two Injury Tracks, One Judge

The Ozempic litigation isn't one claim - it's two distinct injury sets before the same judge in the Eastern District of Pennsylvania, each reaching a different claimant with different qualifying proof and different case value. Tell us which you're building and we screen to it.

Federal MDL 3094

Gastroparesis & GI Injury

Stomach paralysis, ileus, and bowel obstruction after semaglutide or tirzepatide use.

What the Cases Allege

That the drug caused debilitating GI injury the manufacturers failed to adequately warn about on the label.

Qualifying Proof We Capture

Branded GLP-1 use and duration, the specific GI injury, and objective diagnostic testing - gastric emptying study, motility capsule, or breath test - plus hospitalization records.

Screened to the court's objective-diagnosis standard

Federal MDL 3163 · NJ State

NAION Vision Loss

Sudden, often permanent vision loss linked to GLP-1 use in emerging research.

What the Cases Allege

That GLP-1 use caused non-arteritic anterior ischemic optic neuropathy - a permanent, higher-value injury.

Qualifying Proof We Capture

A formal NAION diagnosis by an ophthalmologist or neuro-ophthalmologist, documentation of sudden painless vision loss and optic disc edema, and records ruling out mimics like giant cell arteritis.

Newer MDL with leadership appointed - early-mover window

Get Pricing for Either Track

From Inquiry to Filable File

How Every Ozempic Lead Is Built

We don't sell raw clicks. Each claimant moves through four stages before it reaches your firm - exclusive, compliant, and screened to the standard that keeps the case alive.

Criteria Build

We map your docket strategy - gastroparesis vs. NAION, hospitalization thresholds, target states - into a custom intake script written for your firm.

Targeted Acquisition

National campaigns across medication-specific SEO and paid social reach the diabetes and weight-loss population. GLP-1 drugs were prescribed everywhere, so coverage is nationwide.

Verification

Lead Insight fraud scanning, live intake-agent screening to your criteria, LexisNexis ID on SSN/address/DOB, and diagnostic-status capture on every file.

Exclusive Delivery

Compliant, CRM-integrated claimant files delivered to your firm only - with questionnaire and required forms attached. Real-time or live transfer to remove lag.

The Economics, Straight

Build Verified Inventory Before the Window Closes

GLP-1 acquisition costs are still in the window before bellwether verdicts reprice the tort. Once early trial values land, costs are widely expected to climb - and firms that built verified inventory now hold a cost advantage later arrivals won't catch.

We structure to your model and put it in writing before you spend a dollar. Every claimant is backed by our guarantee: if a lead isn't to spec, we replace it free. Qualified claimants, or you don't pay.

PPLPay-Per-Lead - you buy qualified, verified inquiries and run your own intake. Lower entry, your team carries conversion.

PPCPay-Per-Signed-Case - you buy the outcome: a litigation-ready signed retainer that's already cleared screening.

GLP-1 case acquisition cost trends and the bellwether pricing window for plaintiff law firms building an Ozempic docket

Why Timing Matters

Now · 2026

Acquisition window open. Costs sit ahead of bellwether pricing. Statutes of limitations are running - the time to build docket is now.

2026 · Daubert & Causation

Expert challenges tested. Defense moves to exclude plaintiffs' experts. Verified inventory survives; unverified files get discounted.

Late 2026 → 2027

Bellwether trials. First trials set case values - and reprice the cost of acquiring claimants for everyone who waited.

Get Campaign Pricing

Litigation status current as of June 2026

Where the Ozempic Litigation Stands

The GLP-1 docket is moving fast. These are the facts shaping case acquisition right now - ask us for the current posture before you launch.

2Active federal MDLs (3094 & 3163), E.D. Pa.

3,700+Pending GI cases in MDL 3094 - still growing

2Named defendants: Novo Nordisk & Eli Lilly

$0Global settlement so far - trials expected '26–'27

Objective-diagnosis ruling in forceGastroparesis claims must show a gastric emptying study or comparable test. This is the single biggest driver of lead value.

NAION MDL is newer, leadership setMDL 3163 was created in late 2025 with a plaintiffs' committee appointed in early 2026 - an earlier-mover window than the GI track.

Full Compliance

Built on Industry Standards

Operating since 2009, we've developed processes that ensure potential leads are treated fairly and their privacy respected. On a medical-injury tort, clean provenance and verified identity protect the integrity of every file. We achieve full compliance with TCPA, HIPAA, ABA, and federal and state statutes.

GDPR

HIPAA

TCPA

CCPA

ABA

GDPR

HIPAA

TCPA

CCPA

ABA

Decades of Experience

Get Your Ozempic Leads From a Partner You Can Trust

Ozempic cases are won and lost on documentation - the right diagnostic proof and a carefully handled intake separate a filable case from a dead end. If you're looking for a marketing agency that delivers leads you can build into real cases, count on the one that has provided more than 60,000 across areas of practice for nearly 20 years.

Get Your No-Hassle Quote Call (800) 889-1679

15 Years of Experience - Injury Case Claims

Get Started

Get Your Ozempic Leads
Quote Today

If your firm is looking for authentic legal marketing for case leads for your Ozempic, GLP-1, or broader mass tort docket, give us the opportunity to earn your business.

We promise the best quality with the industry's best return policy. No other company offers investment protection like we do.

✓ Qualified Claimants Matched to Your Criteria

✓ Screened to the MDL's Diagnostic Standard

✓ 60,000+ Leads Delivered Since 2009

✓ LexisNexis ID-Verified Claimants

✓ Exclusive - Leads Are Never Resold

✓ TCPA, HIPAA & ABA Compliant

10:11

Recent Leads

Recent Leads Appointments Notifications

Real-Time Leads

Instant updates so you never miss an opportunity.

Qualified Cases

Every lead is pre-screened and ready to convert.

Maximum Results

Our technology connects you with high-value cases.

Secure & Reliable

Your data and leads are always protected.

Experience Matters

EST. 2009 ★★★★★

First Name

Last Name

Law Firm Name

Email Address

Phone Number

Ozempic Lead Type of Interest

Tell us about your needs

By submitting, you consent to be contacted by InjuryCaseClaims.com regarding your inquiry. This does not constitute a binding agreement. All information is handled securely and confidentially.

FAQ

Frequently Asked Questions About Ozempic Leads

Everything your firm needs to know before launching your first Ozempic campaign with Injury Case Claims.

Primarily two injury sets that match the active MDLs: gastroparesis, ileus, and bowel obstruction (MDL 3094), and NAION vision loss (MDL 3163), tied to semaglutide and tirzepatide products from Novo Nordisk and Eli Lilly. We screen every lead to the right injury track and capture diagnostic status before delivery.

Exclusive to your firm. We don't resell claimants. A non-exclusive lead in a tort this competitive races three of your competitors to the phone and bleeds out before your intake team can sign it, so every claimant we deliver goes to you only - or via live transfer.

Lead Insight fraud scanning, live intake-agent screening to your custom criteria, LexisNexis ID verification of SSN, address, and date of birth, and capture of diagnostic status - including whether the claimant has the gastric emptying study or ophthalmologic confirmation the court now requires.

Because the MDL court now rejects gastroparesis claims that lack objective testing such as a gastric emptying study. A lead that can't meet that bar isn't a case - it's wasted intake labor. We screen for diagnostic posture up front so your team isn't chasing files the court will throw out, and so your inventory holds value through Daubert and bellwether events.

Both. We structure to your model and your docket strategy - per qualified lead or per signed retainer - and quote it in writing before you commit a dollar. Pricing depends on injury type, verification depth, exclusivity, and volume.

Following onboarding, Injury Case Claims strives to deliver leads in as little as three to five days from the start of a campaign, depending on the injury track, geography, and screening criteria you set.

Your firm selects the screening requirements that give each case the best chance of success. If a lead doesn't match your criteria, we replace it at no additional cost - qualified claimants, or you don't pay.